Sirolimus compounded vs brand name: what actually differs

Last updated 2026-07-30

Are compounded sirolimus and brand-name sirolimus the same drug?

Yes, chemically. Sirolimus is the generic name; rapamycin is the older, original name for the same molecule, first isolated from a soil bacterium found on Easter Island (Rapa Nui) ^[1]. Wyeth (later Pfizer) brought it to market as Rapamune, approved by the FDA in 1999 to prevent organ rejection in kidney transplant patients ^[2]. Generic sirolimus tablets and oral solution have been FDA-approved for years and are manufactured by companies like Zydus and Par Pharmaceutical under the same rules as any other generic drug. Compounded sirolimus is different in one important way: it isn't a finished, FDA-approved drug product. A compounding pharmacy takes active pharmaceutical ingredient (API) sirolimus powder and formulates it into capsules or a solution to a specific dose, often one that doesn't exist commercially (like a 3 mg or 4 mg capsule, or a low-dose weekly formulation). The molecule is identical. The manufacturing pathway, oversight, and quality assurance are not. This matters because almost everyone taking sirolimus for longevity purposes, rather than transplant rejection, is taking it off-label. The FDA has not approved sirolimus or rapamycin for aging, lifespan extension, or any anti-aging indication. That gap is the whole story behind why compounding exists in this space at all: intermittent, low-dose protocols popular in longevity circles (often 5-6 mg once weekly) don't match any commercially available tablet strength.

What does FDA approval actually mean for brand-name sirolimus?

FDA approval for Rapamune means the finished product, the exact tablet or liquid you'd get from a pharmacy, went through clinical trials, has an approved label, and gets manufactured under strict Current Good Manufacturing Practice (cGMP) rules with batch-to-batch testing for potency, purity, and dissolution ^[2][3]. The approved label is specifically for prophylaxis of organ rejection in renal transplant patients aged 13 and older ^[2]. Generic sirolimus (non-compounded) has to prove bioequivalence to Rapamune, meaning it delivers the same drug into the bloodstream at the same rate and extent, before the FDA approves it as an AB-rated substitute. Once approved, it's held to the same cGMP standard as any other generic. Compounded drugs skip this pathway entirely. Under federal law, compounded preparations are exempt from FDA's premarket approval and cGMP requirements as long as they meet the conditions of Section 503A of the Federal Food, Drug, and Cosmetic Act, which covers pharmacies compounding for an individual patient with a valid prescription ^[4]. Section 503B allows larger "outsourcing facilities" to compound in bulk under closer FDA oversight, including cGMP compliance, but 503B facilities are still not required to prove clinical bioequivalence for each formulation the way generic manufacturers are ^[5].

Why do people use compounded sirolimus instead of the FDA-approved version?

Three reasons come up constantly: dose flexibility, cost, and access. Rapamune and generic sirolimus come in fixed strengths, 1 mg and 2 mg tablets, or a 1 mg/mL oral solution. Longevity protocols, borrowed loosely from the intermittent, high-dose-but-infrequent dosing strategy used in the NIA Interventions Testing Program mouse studies, often call for 5, 6, or even 8-10 mg once a week, sometimes for only part of the month. Getting there with standard tablets means swallowing multiple pills, and pill-splitting a scored tablet is one thing, splitting a 1 mg tablet into thirds is not something any pharmacist recommends. Compounding pharmacies can make a single 5 mg or 6 mg capsule, which is more convenient and, proponents argue, more consistent than stacking commercial tablets. Cost is the bigger driver in practice. Brand-name Rapamune without insurance runs several hundred dollars a month; generic sirolimus tablets are meaningfully cheaper but still not trivial, and neither is typically covered by insurance when prescribed off-label for a healthy adult, since insurers pay based on FDA-approved indications. Compounded sirolimus, sourced through a telehealth or longevity-focused prescriber network, commonly runs somewhere in the $60-150 per month range depending on dose and pharmacy, though exact pricing varies a lot and isn't standardized or publicly posted the way retail drug prices are.

Is compounded sirolimus FDA-approved or regulated?

No. Compounded sirolimus is not an FDA-approved drug product. It's legal to prescribe and dispense under state pharmacy law and, for human use, under FD&C Act Sections 503A and 503B, but the finished capsule or solution itself never went through an FDA approval application ^[4][5]. The FDA has been explicit that compounded drugs "are not FDA-approved," meaning the agency has not verified their safety, effectiveness, or manufacturing quality the way it does for approved drugs, and the agency has flagged quality problems at compounding pharmacies in the past, including contamination incidents that led to serious patient harm at 503B-type facilities ^[6]. That history is why the 503B outsourcing facility category was created in 2013 after the New England Compounding Center meningitis outbreak, in which contaminated compounded steroid injections caused over 750 infections and more than 60 deaths ^[7]. Sirolimus compounding hasn't been linked to anything like that, but the regulatory gap is real and worth knowing about before you choose a pharmacy based on price alone.

How does the cost of compounded sirolimus compare to brand-name Rapamune?

Here's a rough comparison based on typical U.S. list and cash pricing patterns for these products. Actual prices vary by pharmacy, dose, insurance status, and whether you use a discount card, so treat this as a general shape rather than a quote. | Option | Typical monthly cost (cash, off-label use) | FDA-approved product? | Dose flexibility |

What are the risks of using compounded sirolimus for longevity?

The core drug risks are the same regardless of source, because the molecule is identical. Sirolimus is an mTOR inhibitor and, at transplant doses, a genuine immunosuppressant. Even at the lower, intermittent doses used off-label, it still affects immune function, and mouth ulcers (stomatitis) are one of the most commonly reported side effects in both the transplant literature and anecdotal longevity use ^[2]. Metabolic effects, including elevated triglycerides, cholesterol changes, and in some cases new-onset insulin resistance or hyperglycemia, are documented in the Rapamune label and package insert ^[2]. There is no completed human lifespan trial for sirolimus. Full stop. The strongest evidence for lifespan extension comes from mice, specifically the National Institute on Aging's Interventions Testing Program, which found that rapamycin extended median lifespan in genetically heterogeneous mice by around 9-14% in males and up to roughly 18-21% in some cohorts, even when started later in life ^[8][9]. That's a real, replicated, and fairly remarkable finding across multiple independent labs. But mice are not humans, dosing protocols in mice don't map cleanly onto human weekly dosing schedules, and nobody has published a completed randomized controlled trial showing sirolimus extends human lifespan or healthspan. Small human studies (like the 2014 Mannick trial on immune function in elderly adults, using an mTOR inhibitor related to sirolimus) looked at surrogate markers like vaccine response, not lifespan ^[10]. The compounding-specific risk layer sits on top of that: potency variability. Compounded capsules aren't required to pass the same batch dissolution and content-uniformity testing FDA-approved generics must pass, so there's more room for a given capsule to be meaningfully over or under the labeled dose. For a drug with a narrow therapeutic range and real immunosuppressive effects, that variability isn't a small footnote. It's a real practical risk, and it's the main reason pharmacy choice matters more with compounded sirolimus than it does with a bottle of a generic statin.

How do I know if a compounding pharmacy is trustworthy?

Look for a few concrete things. First, is the pharmacy licensed in your state and, ideally, accredited by the Pharmacy Compounding Accreditation Board (PCAB), which audits compounding pharmacies against USP quality standards? Second, does it operate as a 503A pharmacy filling individual prescriptions from a licensed prescriber, or a 503B outsourcing facility registered with the FDA, which involves more oversight? You can check a facility's 503B registration status on the FDA's own outsourcing facility list ^[5]. Third, ask whether the pharmacy tests for potency and sterility on the batches it produces, and whether it will show you a certificate of analysis. A pharmacy that won't answer these questions plainly is a red flag, regardless of how good its pricing looks. This is also where working with a provider-reviewed pathway helps rather than sourcing sirolimus from an unverified online seller. Sirolimus Rx connects patients with licensed prescribers who work with vetted pharmacy partners, rather than compounding anything itself; the point is provider oversight plus a pharmacy relationship you can actually check, not a mystery capsule from an anonymous website.

Does compounded sirolimus work as well as brand-name Rapamune?

For the approved transplant indication, brand and FDA-approved generic sirolimus have proven bioequivalence data behind them, so "works as well" has an actual clinical answer: yes, generics are required to match. Compounded versions used for that indication are rare and generally discouraged, because transplant patients need very tight, reliable blood levels to avoid organ rejection or toxicity, and compounded variability is a real concern there. For off-label longevity use, the honest answer is that nobody knows, because there's no human trial comparing outcomes on compounded versus brand sirolimus for aging or lifespan endpoints, and there's no human lifespan trial for either formulation at all. What we can say is that both deliver the same molecule to the bloodstream, assuming the compounded product is made accurately; the open question is potency consistency, not pharmacology. If you want to understand what people report experiencing on sirolimus protocols, sirolimus reviews and sirolimus before and after reports are the closest thing to real-world signal available right now, though they're self-reported and not controlled data.

What dose strengths are available compounded that aren't available commercially?

Commercial sirolimus comes in 1 mg and 2 mg tablets and a 1 mg/mL oral solution. Compounding pharmacies commonly produce 3 mg, 4 mg, 5 mg, 6 mg, and sometimes higher single capsules, matching the weekly or twice-weekly regimens discussed in longevity literature and used informally by prescribers following the ITP-inspired dosing logic. This is the single most practical reason compounding exists in this space: matching a once-weekly 5-6 mg target dose with commercial 1 mg tablets means swallowing five or six pills, which is more than inconvenient but makes partial-dose errors more likely. Whether a 5 mg or 6 mg weekly dose is the "right" human dose for any longevity benefit is unresolved. Protocols in circulation are extrapolated from mouse trough-blood-level targets and small human pharmacokinetic studies, not from a trial that measured human aging outcomes at that specific dose.

What should I ask my doctor before switching between compounded and brand sirolimus?

Ask whether your prescriber has experience monitoring sirolimus blood levels, since trough levels (measured by a blood draw, typically drawn immediately before the next dose) are the standard way to confirm you're getting a consistent, appropriately dosed amount, regardless of source ^[2]. This is arguably more important with compounded product, precisely because you can't rely on cGMP batch testing the way you can with an FDA-approved tablet. Ask about baseline and follow-up labs: lipid panel, fasting glucose or HbA1c, complete blood count, and kidney function, given sirolimus's known metabolic and immune effects. Ask what pharmacy the prescriber uses and whether it's PCAB-accredited or FDA-registered as a 503B facility. And ask directly whether switching formulations (brand to compounded, or between compounding pharmacies) will trigger a repeat blood level check, since potency can differ between sources even when the labeled dose is identical.

Is switching from compounded to brand-name sirolimus (or back) safe?

It can be, but it isn't something to do casually. Because compounded products aren't bound to the same bioequivalence standard as FDA-approved generics, a 5 mg compounded capsule and a hypothetical 5 mg dose built from commercial tablets may not deliver identical blood levels. Clinicians managing transplant patients take this seriously enough that guidance around therapeutic drug monitoring exists specifically because sirolimus has a narrow therapeutic index, meaning the gap between an effective dose and a toxic one is relatively small ^[2]. For someone on a longevity protocol, the practical move is to treat any switch, brand to compounded, one compounding pharmacy to another, or one dose format to another, as a reason to re-check labs and go slow, not assume equivalence. This is a place where working with a provider who actually tracks your labs over time, rather than a one-time online order, earns its cost.

Frequently asked questions

Is rapamycin the same as sirolimus?

Yes. Rapamycin is the original name for the compound, discovered in a soil sample from Easter Island (Rapa Nui) in the 1970s ^[1]. Sirolimus is the generic drug name used once it entered clinical development and FDA approval. They're the same molecule; the names are used interchangeably in both medical literature and longevity discussions.

Why is sirolimus compounded instead of just prescribed as Rapamune?

Mainly for dose flexibility and cost. Commercial sirolimus comes only in 1 mg and 2 mg tablets, but off-label longevity protocols often call for 5-6 mg weekly doses. Compounding pharmacies can make custom-strength capsules that avoid stacking multiple commercial pills, and compounded product is typically cheaper for patients paying cash since insurance rarely covers off-label use.

Is compounded sirolimus legal?

Yes, when dispensed by a licensed pharmacy with a valid prescription, under FD&C Act Section 503A (individual patient compounding) or 503B (registered outsourcing facilities) ^[4][5]. It's legal but not FDA-approved as a finished product; the agency doesn't verify its safety or potency batch-by-batch the way it does for approved generics.

Does sirolimus actually extend human lifespan?

There's no completed human trial showing this. The strong evidence is in mice: the NIA's Interventions Testing Program found rapamycin extended median mouse lifespan by roughly 9-14% (and more in some cohorts), even started late in life ^[8][9]. Human data is limited to small trials on immune and metabolic markers, not lifespan itself.

What are the main side effects of sirolimus?

Mouth ulcers (stomatitis), elevated triglycerides and cholesterol, immune suppression, and in some cases increased blood sugar are the most commonly reported effects, per the Rapamune prescribing information ^[2]. These occur regardless of whether the drug is brand, generic, or compounded, since they're pharmacologic effects of the molecule itself.

How much does compounded sirolimus cost compared to Rapamune?

Compounded sirolimus commonly runs about $60-150 per month depending on dose and pharmacy, while brand Rapamune without insurance often runs $400-700 or more monthly. Generic FDA-approved sirolimus tablets fall in between, typically $100-300. None of these are usually insurance-covered for off-label longevity use.

Is compounded sirolimus as potent as brand-name sirolimus?

The active ingredient is the same molecule, but compounded products aren't required to pass the same batch-by-batch potency and dissolution testing that FDA-approved generics must pass under cGMP rules. That means there's more room for capsule-to-capsule variability, which is why choosing an accredited, tested pharmacy matters more with compounded product.

Can I split a Rapamune tablet to get a lower or custom dose?

Splitting scored tablets as directed is sometimes fine, but 1 mg tablets are small, and precisely splitting them into thirds or quarters to hit an odd dose isn't reliable or recommended. This dosing mismatch is one of the practical reasons people turn to compounded capsules made to an exact custom strength instead.

What blood tests should I get while on sirolimus?

Standard monitoring includes sirolimus trough blood levels, a fasting lipid panel, fasting glucose or HbA1c, complete blood count, and kidney function tests. These track the drug's known effects on lipids, blood sugar, immune cells, and kidneys, and trough levels confirm you're getting a consistent, appropriately dosed amount ^[2].

Is it safe to switch between different sirolimus sources?

It can be safe with monitoring, but don't assume automatic equivalence. Because compounded formulations aren't bound to the same bioequivalence standard as approved generics, switching brands, compounding pharmacies, or dose formats is a reasonable trigger for a repeat blood level check, especially given sirolimus's narrow therapeutic index ^[2].

Is sirolimus FDA-approved for anti-aging use?

No. Sirolimus is FDA-approved only for preventing organ transplant rejection, and formulations like Fyarro and Hyftor are approved for specific cancer and skin conditions ^[2]. Any use for aging, lifespan extension, or general longevity is entirely off-label, meaning the FDA has not evaluated it for that purpose.

Who should avoid sirolimus entirely?

People with active infections, poorly controlled lipid disorders, significant kidney impairment, or anyone pregnant or planning pregnancy should generally avoid sirolimus, given its immunosuppressive and metabolic effects noted in the prescribing information ^[2]. Anyone considering it off-label should be screened and monitored by a prescriber familiar with the drug, not self-directed.

Sources

1. NIH National Center for Biotechnology Information, PubChem: Sirolimus: Sirolimus (rapamycin) was originally isolated from Streptomyces hygroscopicus found in soil from Easter Island (Rapa Nui)
2. FDA, Rapamune (sirolimus) full prescribing information: Rapamune's FDA-approved indication, dosing, and documented side effects including stomatitis and lipid elevation
3. FDA, Facts about Current Good Manufacturing Practice (cGMP): FDA-approved drugs must be manufactured under cGMP with batch testing for potency and purity
4. FDA, Human Drug Compounding Under Section 503A: Compounding pharmacies filling individual prescriptions operate under Section 503A of the FD&C Act, exempt from premarket approval requirements
5. FDA, Outsourcing Facilities under Section 503B: 503B outsourcing facilities register with FDA and are subject to cGMP but not required to prove clinical bioequivalence per formulation
6. FDA, Compounded Drugs page: FDA states compounded drugs are not FDA-approved and the agency does not verify their safety or effectiveness before they reach patients
7. CDC, Multistate Outbreak of Fungal Meningitis Associated with Compounded Steroid Injections: The 2012 New England Compounding Center outbreak caused over 750 infections and more than 60 deaths, leading to creation of the 503B category
8. Harrison DE et al., Nature (2009), NIA Interventions Testing Program: Rapamycin extended median and maximal lifespan in genetically heterogeneous mice even when started late in life, per the NIA Interventions Testing Program
9. Miller RA et al., Journals of Gerontology Series A (2011): Rapamycin extended lifespan in mice by roughly 9-14% in males across ITP cohorts with dose-dependent effects
10. Mannick JB et al., Science Translational Medicine (2014): An mTOR inhibitor improved immune (vaccine) response markers in elderly adults in a controlled human trial, without measuring lifespan